---
title: "Understanding the Market | ASCLETIS-B is currently up over 4% as the company has completed preliminary communication with the National Medical Products Administration regarding the new drug application for Denifasirt"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/261183817.md"
description: "ASCLETIS-B is currently up over 4%, as of the time of publication, up 4.29%, priced at HKD 9.49, with a transaction volume of HKD 23.5801 million. In terms of news, ASCLETIS announced that it has recently completed Pre-NDA communication with the National Medical Products Administration of China regarding the new drug application for the treatment of moderate to severe acne with the drug ASC40, and plans to submit the new drug application soon. The Pre-NDA communication began in June 2025 and ended in October 2025. Additionally, ASCLETIS recently announced that it has selected a candidate drug, ASC35, which is expected to become a best-in-class monthly subcutaneous injection GLP-1 receptor (GLP-1R)/GIP receptor (GIPR) dual-target agonist peptide for clinical development. ASCLETIS expects to submit an IND application for ASC35 for the treatment of obesity to the U.S. Food and Drug Administration (FDA) in the second quarter of 2026. ASC35 is being developed as both a monotherapy and combination therapy for the treatment of cardiometabolic diseases, including obesity, diabetes, and metabolic dysfunction-associated steatotic liver disease (MASH)"
datetime: "2025-10-15T06:06:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/261183817.md)
  - [en](https://longbridge.com/en/news/261183817.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/261183817.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/261183817.md) | [繁體中文](https://longbridge.com/zh-HK/news/261183817.md)


# Understanding the Market | ASCLETIS-B is currently up over 4% as the company has completed preliminary communication with the National Medical Products Administration regarding the new drug application for Denifasirt

According to the Zhitong Finance APP, ASCLETIS-B (01672) is currently up over 4%, with a rise of 4.29% as of the time of writing, priced at HKD 9.49, with a transaction volume of HKD 23.5801 million.

In terms of news, ASCLETIS announced that it has recently completed Pre-NDA communication with the National Medical Products Administration of China regarding the new drug application for the treatment of moderate to severe acne with Dapansutrile (ASC40), and plans to submit the new drug application soon. The Pre-NDA communication began in June 2025 and ended in October 2025.

Additionally, ASCLETIS recently announced that it has selected a candidate drug, ASC35, which is expected to become a best-in-class once-monthly subcutaneous GLP-1 receptor (GLP-1R)/GIP receptor (GIPR) dual-target agonist peptide for clinical development. ASCLETIS expects to submit an IND application for ASC35 for the treatment of obesity to the U.S. Food and Drug Administration (FDA) in the second quarter of 2026. ASC35 is being developed as both a monotherapy and combination therapy for the treatment of cardiometabolic diseases, including obesity, diabetes, and metabolic dysfunction-associated steatotic liver disease (MASH)

### 相关股票

- [ASCLETIS-B (01672.HK)](https://longbridge.com/zh-CN/quote/01672.HK.md)

## 相关资讯与研究

- [Simcere Pharmaceutical Group Limited (2096) Receives a Buy from Bank of China](https://longbridge.com/zh-CN/news/281137424.md)
- [Pony AI Inc. Announces Results of Extraordinary General Meeting, Class A Meeting, and Class B Meeting | PONY Stock News](https://longbridge.com/zh-CN/news/281518748.md)
- [03:02 ETSyneron Bio Announces Completion of $150 Million Series B Financing](https://longbridge.com/zh-CN/news/281612425.md)
- [Nomura Adjusts Hansoh Pharmaceutical Group's Price Target to HK$38 From HK$37.87, Keeps at Neutral](https://longbridge.com/zh-CN/news/281164648.md)
- [Xiaomi bought back 12.8 million type B shares for HK$395.1 million on April 2, HKEX says](https://longbridge.com/zh-CN/news/281550229.md)